Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK

Nicholas M. Brown; Anna L. Goodman; Carolyne Horner; Abi Jenkins; Erwin M. Brown

doi:10.1093/jacamr/dlaa114

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK

Nicholas M. Brown^*
, Anna L. Goodman
, Carolyne Horner
, Abi Jenkins
, Erwin M. Brown

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

154 Citations (Scopus)

Abstract

These evidence-based guidelines are an updated version of those issued in 2008. They have beenproduced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, takinginto account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.

Original language	English
Article number	dlaa114
Journal	JAC-Antimicrobial Resistance
Volume	3
Issue number	1
DOIs	https://doi.org/10.1093/jacamr/dlaa114
Publication status	Published - 1 Mar 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jacamr/dlaa114

Cite this

@article{1e9167b9f6d44072b795a8631c657988,

title = "Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK",

abstract = "These evidence-based guidelines are an updated version of those issued in 2008. They have beenproduced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, takinginto account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.",

author = "Brown, \{Nicholas M.\} and Goodman, \{Anna L.\} and Carolyne Horner and Abi Jenkins and Brown, \{Erwin M.\}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.",

year = "2021",

month = mar,

day = "1",

doi = "10.1093/jacamr/dlaa114",

language = "English",

volume = "3",

journal = "JAC-Antimicrobial Resistance",

issn = "2632-1823",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Treatment of methicillin-resistant Staphylococcus aureus (MRSA)

T2 - Updated guidelines from the UK

AU - Brown, Nicholas M.

AU - Goodman, Anna L.

AU - Horner, Carolyne

AU - Jenkins, Abi

AU - Brown, Erwin M.

PY - 2021/3/1

Y1 - 2021/3/1

N2 - These evidence-based guidelines are an updated version of those issued in 2008. They have beenproduced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, takinginto account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.

AB - These evidence-based guidelines are an updated version of those issued in 2008. They have beenproduced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, takinginto account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.

UR - https://www.scopus.com/pages/publications/85108066235

U2 - 10.1093/jacamr/dlaa114

DO - 10.1093/jacamr/dlaa114

M3 - Review article

C2 - 33582806

AN - SCOPUS:85108066235

SN - 2632-1823

VL - 3

JO - JAC-Antimicrobial Resistance

JF - JAC-Antimicrobial Resistance

IS - 1

M1 - dlaa114

ER -

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this